A practical reference on Visceral adiposity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
The prostate consists of glandular and connective tissue. Tall column-shaped cells form the lining (the epithelium) of the glands. These form one layer or may be pseudostratified. The epithelium is highly variable and areas of low cuboidal or flat cells can also be present, with transitional epithelium in the outer regions of the longer ducts. Basal cells surround the luminal epithelial cells in benign glands. The glands are formed as many follicles, which drain into canals and subsequently 12–20 main ducts. These in turn drain into the urethra as it passes through the prostate. There are also a small amount of flat cells, which sit next to the basement membranes of glands, and act as stem cells. The connective tissue of the prostate is made up of fibrous tissue and smooth muscle. The fibrous tissue separates the gland into lobules. It also sits between the glands and is composed of randomly orientated smooth-muscle bundles that are continuous with the bladder. Over time, thickened secretions called corpora amylacea accumulate in the gland.
== Reproduction == Zearalenone structure is similar to estrogens and α-zearalenol binds with an even greater affinity estrogen receptors, while β-zearalenol's affinity is lower than both the parent compound's and α-Zel's binding affinity. This identifies ZEN and its metabolites as xenoestrogens. The human and livestock exposure to ZEN through the diet poses health concern due to the onset of several sexual disorders and alterations in the development of sexual organs. There are reliable case reports of early puberty in girls chronically exposed to ZEN in various regions of the world. In mice, ZEN consumption was linked to a decline of potent sperm and egg cells, an increase to double-stranded breaks in DNA and activation of DNA repair mechanisms, followed by embryonic development challenges that reduced the viability of offspring.
=== Insulin-induced hypokalemia === Insulin can also cause postprandial somnolence via another mechanism. Insulin increases the activity of Na/K ATPase, causing increased movement of potassium into cells from the extracellular fluid. The large movement of potassium from the extracellular fluid can lead to a mild hypokalemic state. The effects of hypokalemia can include fatigue, muscle weakness, or paralysis. The severity of the hypokalemic state can be evaluated using Fuller's Criteria. Stage 1 is characterized by no symptoms but mild hypokalemia. Stage 2 is characterized with symptoms and mild hypokalemia. Stage 3 is characterized by only moderate to severe hypokalemia.
=== Isotope labeling measuring techniques === Any technique in measuring the difference between isotopomers can be used. The two primary methods, nuclear magnetic resonance (NMR) and mass spectrometry (MS), have been developed for measuring mass isotopomers in stable isotope labeling. Proton NMR was the first technique used for 13C-labeling experiments. Using this method, each single protonated carbon position inside a particular metabolite pool can be observed separately from the other positions. This allows the percentage of isotopomers labeled at that specific position to be known. The limit to proton NMR is that if there are n carbon atoms in a metabolite, there can only be at most n different positional enrichment values, which is only a small fraction of the total isotopomer information. Although the use of proton NMR labeling is limiting, pure proton NMR experiments are much easier to evaluate than experiments with more isotopomer information. In addition to Proton NMR, using 13C NMR techniques will allow a more detailed view of the distribution of the isotopomers. A labeled carbon atom will produce different hyperfine splitting signals depending on the labeling state of its direct neighbors in the molecule. A singlet peak emerges if the neighboring carbon atoms are not labeled. A doublet peak emerges if only one neighboring carbon atom is labeled. The size of the doublet split depends on the functional group of the neighboring carbon atom.
S100 calcium-binding protein B (S100B) is a protein of the S100 protein family. S100 proteins are localized in the cytoplasm and nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21; however, this gene is located at 21q22.3.
Sources: en.wikipedia.org
=== Thermal === Fluorinated polymers like PTFE and PVDF are especially thermally stable due to strong carbon-fluorine (C–F) bonds, the strongest in organic chemistry, which contribute to the durability of these materials under heat. PVDF is semi-crystalline, giving it a balance of rigidity and flexibility across temperatures from −35 °C to 160 °C. Above 316 °C, PVDF decomposes via dehydrofluorination, which can lead to structural changes, including double bonds and potential discoloration from thermal decomposition.
For services to Association Football and to Gender Equality. Rajwinder Singh. Principal Project Sponsor, Prison Infrastructure Team, Ministry of Justice. For Public Service. Dr. Sabesan Sithamparanathan, FREng. Founder and President, PervasID and Enterprise Fellow, Girton College, University of Cambridge. For services to Innovation Technology. David Alexander Smith. Departmental Records Officer and Chief Librarian, Department for Levelling Up, Housing and Communities. For services to Government Knowledge and Information Management. Marie Smith. Senior Officer, National Crime Agency. For services to Law Enforcement. Michelle Southern. Founder and Director, Street Paws. For services to Homeless People and their Pets. David Martin Sprackling. Lately Lawyer, Parliamentary Counsel, Office of the Parliamentary Counsel. For Public Service. Nicholas Stace. Chair, The Conduit Holding Company. For services to Consumers and to the Environment. Marc Howard Steene. Founder and Director, Outside In Art. For services to Art. Gavin Paul Stollar. Honorary Chair, Liberal Democrat Friends of Israel. For political service to the Jewish Community. Luigi Strinati. Delivery Director, HM Courts and Tribunals Service Wales. For Public Service. Lorraine Pfavayi Sunduza. Lately Chief Nurse, East London NHS Foundation Trust. For services to Mental and Community Health. Joanna Kathryn Swash. Group Chief Executive Officer, Moneypenny. For services to the Economy. Claire Louise Swift. Director of Social Responsibility, Making for Change. For services to the Rehabilitation of Prisoners.
Wilk noted how "brave whistleblowers from the lab risked their livelihoods to expose unlicensed lab techs sleeping on the job, a lack of supervision over untrained staff, contaminated tests, swapped samples, testing errors, a high rate of "inconclusive" results, and inaccurate results, with no process for addressing or rectifying errors" were subsequently "subject to litigation in response to their brave actions to expose the abuse of state funding in the lab, and the potential public health issues stemming from improperly processing and handling COVID 19 specimens." The bill passed unanimously in the California State Senate, but died in the California State Assembly. The CPDH partnership contract with PerkinElmer was terminated on May 15, 2022, and was subsequently criticized for its excess costs, failure to meet expectations, and the state's poor handling of the investigation.
=== CAT scans === CAT scans can be used to infer the 3D structure of a fossil egg's interior by compiling images taken of slices through the egg in small regular increments. Scientists have tried to use CAT scans to look for embryo fossils contained inside the egg without having to damage the egg itself by physically extracting them. However, as of Ken Carpenter's 1999 book on dinosaur eggs, Eggs, Nests, and Baby Dinosaurs, all alleged embryos discovered using this method were actually false alarms. Variations in the type of infilling mineral or cement binding the infilling sediment into rock sometimes resemble bones in CAT scan images. Sometimes eggshell fragments that fell back into the egg when it hatched have been mistaken for embryonic bones. The use of CAT scans to search for embryonic remains is actually conceptually flawed since embryonic bones have not yet mineralized. Since the infilling sediment is their only source of minerals they will be preserved at basically the same density and therefore have poor visibility in the scan. The validity of this issue has been confirmed by performing Cat scans on fossil eggs known to have embryos inside and noting their poor visibility in the scan images. The only truly reliable way to discover a dinosaur embryo is to cut the egg open or dissolve some of its eggshell away.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.